Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
29
SLRX Quote, Financials, Valuation and Earnings
Last price:
$0.67
Seasonality move
:
-13.79%
Day range:
$0.64 - $0.68
52-week range:
$0.62 - $108.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.08x
Volume:
70.4K
Avg. volume:
422.1K
1-year change:
-97.65%
Market cap:
$330.7K
Revenue:
--
EPS (TTM):
-$24.85
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Salarius Pharmaceuticals, Inc. has 60010.95% upside to fair value with a price target of -- per share.
SLRX vs. S&P 500
-
Over the past 5 trading days, Salarius Pharmaceuticals, Inc. has overperformed the S&P 500 by 0.71% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Salarius Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Salarius Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Salarius Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Salarius Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Salarius Pharmaceuticals, Inc. reported earnings per share of -$1.81.
Enterprise value:
-4.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4.4K
Return On Assets:
-149.74%
Net Income Margin (TTM):
--
Return On Equity:
-316.09%
Return On Invested Capital:
-291.67%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$10.6K | -$4.4K | -$4.4K | -$1.1K | -$1.1K | |
| Operating Income | -$18.4M | -$5.2M | -$5.1M | -$1M | -$895.1K | |
| EBITDA | -$18.4M | -$5.2M | -$5.1M | -$1M | -$894K | |
| Diluted EPS | -$57.13 | -$8.19 | -$24.85 | -$0.76 | -$1.81 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.2M | $18M | $8.3M | $3.8M | $5.2M | |
| Total Assets | $44.3M | $19.7M | $8.4M | $3.9M | $6.1M | |
| Current Liabilities | $1.6M | $3.1M | $2.3M | $934.6K | $1.8M | |
| Total Liabilities | $1.6M | $3.1M | $2.3M | $934.6K | $1.8M | |
| Total Equity | $42.7M | $16.6M | $6.1M | $2.9M | $4.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16M | -$5.3M | -$4.4M | -$1.4M | -$1.6M | |
| Cash From Investing | -- | -- | -$200K | -- | -$200K | |
| Cash From Financing | $6.8M | $997.5K | $6.2M | $1.4M | $5.9M | |
| Free Cash Flow | -$16M | -$5.3M | -$4.4M | -$1.4M | -$1.6M | |
SLRX
Sector
Market Cap
$330.7K
$28.1M
Price % of 52-Week High
0.6%
50%
Dividend Yield
0%
0%
Shareholder Yield
-346.83%
-1.54%
1-Year Price Total Return
-97.65%
-17.67%
Beta (5-Year)
0.326
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.66
200-day SMA
Sell
Level
$7.51
Bollinger Bands (100)
Sell
Level
1.28 - 5.48
Chaikin Money Flow
Sell
Level
-88.9M
20-day SMA
Sell
Level
$0.75
Relative Strength Index (RSI14)
Sell
Level
25.74
ADX Line
Sell
Level
30.44
Williams %R
Buy
Level
-89.7143
50-day SMA
Sell
Level
$1.67
MACD (12, 26)
Sell
Level
-0.26
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
96.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-42.6488)
Sell
CA Score
(Annual)
Level (-4.8933)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (12.6189)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Stock Forecast FAQ
In the current month, SLRX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SLRX average analyst price target in the past 3 months is --.
-
Where Will Salarius Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Salarius Pharmaceuticals, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Salarius Pharmaceuticals, Inc.?
Analysts are divided on their view about Salarius Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Salarius Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Salarius Pharmaceuticals, Inc.'s Price Target?
The price target for Salarius Pharmaceuticals, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SLRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Salarius Pharmaceuticals, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SLRX?
You can purchase shares of Salarius Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Salarius Pharmaceuticals, Inc. shares.
-
What Is The Salarius Pharmaceuticals, Inc. Share Price Today?
Salarius Pharmaceuticals, Inc. was last trading at $0.67 per share. This represents the most recent stock quote for Salarius Pharmaceuticals, Inc.. Yesterday, Salarius Pharmaceuticals, Inc. closed at $0.65 per share.
-
How To Buy Salarius Pharmaceuticals, Inc. Stock Online?
In order to purchase Salarius Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get SLRX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SLRX
Sector
P/E ratio
--
23.88x
PEG ratio
0.00x
-0.01x
P/B ratio
0.08x
1.82x
Price / LTM sales
--
1.59x
Growth Metrics
SLRX
Sector
Revenue growth
--
4.73%
Earnings growth
-139.15%
11.11%
Revenue (5-year growth)
-100%
6.46%
Earnings forecast
-$53.60
-$0.18
Profitability
SLRX
Sector
Profitability FY 2024
-$4.4K
$3.6M
Return on invested capital
-291.67%
-31.77%
Return on assets
-149.74%
-28.18%
Return on equity
-316.09%
-37.47%
Earnings Date
Last Earnings Date
Jan
3
Next Earnings Date
Jan
3
Estimated Next Earnings Date
Apr
4
Balance Sheet
SLRX
Sector
Total cash
$4.8M
$26.3M
Short term investments
--
$26M
Total assets
$3M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 2
Claritev Corp. [CTEV] is down 20.7% over the past day.
Sell
47
ASTS alert for Jan 2
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
Sell
45
BIDU alert for Jan 2
Baidu, Inc. [BIDU] is up 15.01% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
